Medicus Pharma Ltd (MDCX)

NASDAQ:MDCX

MDCX

Medicus Pharma Ltd

RESEARCH TOOLSreports

Want to see MDCX full AI Analyst Report?

Medicus Pharma Ltd (MDCX) Price & Analysis

252 Followers

MDCX Stock Chart & Stats

$1.46

-$0.29(-9.70%)

At close: Jan 08 4:00 PM EST

$1.46

-$0.29(-9.70%)

Day’s Range― - ―

52-Week Range$0.29 - $8.94

Previous CloseN/A

Volume5.92K

Average Volume (3M)10.17M

Market Cap

$11.89M

Enterprise Value$5.39M

Total Cash (Recent Filing)$6.35M

Total Debt (Recent Filing)$4.00M

Price to Earnings (P/E)―

Beta1.50

Next Earnings

May 28, 2026

EPS Estimate

-0.19

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.57

Shares Outstanding39,362,110

10 Day Avg. Volume13,047,466

30 Day Avg. Volume10,173,042

Financial Highlights & Ratios

PEG Ratio-0.01

Price to Book (P/B)-391.45

Price to Sales (P/S)0.00

P/FCF Ratio-1.16

Enterprise Value/Market Cap0.45

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-0.16

Forecast

1Y Price Target

$6.00

Price Target Upside310.96% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-0.62

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Trial EfficacyPhase 2 top-line data showed a clear treatment benefit with the higher-dose regimen separating from control, supporting progression to later-stage studies.

Licensing And Partnership AppealA license amendment materially lowered royalty obligations while preserving global rights and intellectual property, improving attractiveness for future licensing or partnering deals.

Reduction In Surgical InterventionsA substantial share of treated lesions achieved visible clearance, implying many patients could avoid Mohs surgery and opt for less invasive management, which could expand clinical adoption.

Bears Say

Durability Of Response RiskPrior mid-stage results showed strong initial responses but suboptimal durability at the evaluated dose, indicating a development risk that may require dose or regimen changes.

Placebo Effect And Trial SignalA placebo microneedle patch produced similar histological results to active arms, raising uncertainty about whether observed effects are drug-driven.

Regulatory UncertaintyRegulatory discussions over dose, patch duration, and treatment schedule introduce uncertainty that could change development requirements and timelines.

Medicus Pharma Ltd News

Medicus Pharma submits ODD application to U.S. FDA for SkinJect

Medicus Pharma (MDCX) announced the submission of an Orphan Drug Designation, ODD, application to the U.S. Food and...

3d ago

MDCX

Medicus Pharma enters media partnership with New to The Street

Medicus Pharma (MDCX) entered into a 12-part, one-year strategic media agreement with New to The Street to expand...

12d ago

MDCX

Medicus Pharma submits clinical study design to FDA for Teverelix

Medicus Pharma (MDCX) announced the company has submitted an optimized Phase 2 clinical study design to the FDA...

14d ago

MDCX

Medicus Pharma reports principal investigator validation of Phase 2 data

Medicus Pharma (MDCX) reported independent clinical validation of its Phase 2 SkinJect dataset from Dr. Babar Rao, principal...

20d ago

MDCX

Medicus Pharma Showcases Long-Acting Teverelix Data, Targets Precision Endometriosis Therapy

Medicus Pharma Ltd ( ($MDCX) ) has shared an announcement. Medicus Pharma will present new Phase I data...

4d ago

MDCX

Medicus Pharma Streamlines Phase 2 Teverelix Trial for $2 Billion AUR Market

The latest update is out from Medicus Pharma Ltd ( ($MDCX) ). Medicus Pharma has submitted an optimized...

13d ago

MDCX

Medicus Pharma Sharpens SkinJect Phase 2 Narrative, Pivots to 200µg Dose for Registrational Path

Medicus Pharma Ltd ( ($MDCX) ) has issued an update. Medicus Pharma clarified the interpretation of topline Phase...

18d ago

MDCX

Medicus Pharma’s SkinJect Phase 2 Data Validated by KOL With 80% Response Rate

Medicus Pharma Ltd ( ($MDCX) ) has provided an update. Medicus Pharma reported that key opinion leader and...

20d ago

MDCX

Medicus Pharma’s SkinJect Data Earns KOL Validation With 80% Response in Phase 2

The latest update is out from Medicus Pharma Ltd ( ($MDCX) ). Medicus Pharma reported that key opinion...

20d ago

MDCX

Medicus Pharma Highlights Strong SkinJect Phase 2 Results and AI-Driven Development Plan

An update from Medicus Pharma Ltd ( ($MDCX) ) is now available. Medicus Pharma plans a business update...

24d ago

MDCX

Medicus Pharma Advances SkinJect and Teverelix Pipelines, Adds AI to Clinical Strategy

Medicus Pharma Ltd ( ($MDCX) ) has issued an announcement. Medicus Pharma reported audited full-year 2025 results and...

25d ago

MDCX

Medicus Pharma Showcases Strong Phase 2 SkinJect Data Ahead of Fireside Chat

The latest update is out from Medicus Pharma Ltd ( ($MDCX) ). Medicus Pharma will host a live...

1M ago

MDCX

Medicus Pharma to discuss Skinject Phase 2 reults in fireside chat

Medicus Pharma (MDCX) announced hat members of its executive management team, led by Dr. Raza Bokhari, Executive Chairman...

1M ago

MDCX

Medicus Pharma Highlights Strong Phase 2 SkinJect Data Ahead of Business Update Call

An update from Medicus Pharma Ltd ( ($MDCX) ) is now available. Medicus Pharma will host a March...

1M ago

MDCX

MDCX FAQ

What was Medicus Pharma Ltd’s price range in the past 12 months?

Medicus Pharma Ltd lowest stock price was $0.29 and its highest was $8.94 in the past 12 months.

What is Medicus Pharma Ltd’s market cap?

Medicus Pharma Ltd’s market cap is $11.89M.

When is Medicus Pharma Ltd’s upcoming earnings report date?

Medicus Pharma Ltd’s upcoming earnings report date is May 28, 2026 which is in 38 days.

How were Medicus Pharma Ltd’s earnings last quarter?

Medicus Pharma Ltd released its earnings results on Mar 25, 2026. The company reported -$0.575 earnings per share for the quarter, missing the consensus estimate of -$0.07 by -$0.505.

Is Medicus Pharma Ltd overvalued?

According to Wall Street analysts Medicus Pharma Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Medicus Pharma Ltd pay dividends?

Medicus Pharma Ltd does not currently pay dividends.

What is Medicus Pharma Ltd’s EPS estimate?

Medicus Pharma Ltd’s EPS estimate is -0.19.

How many shares outstanding does Medicus Pharma Ltd have?

Medicus Pharma Ltd has 39,362,110 shares outstanding.

What happened to Medicus Pharma Ltd’s price movement after its last earnings report?

Medicus Pharma Ltd reported an EPS of -$0.575 in its last earnings report, missing expectations of -$0.07. Following the earnings report the stock price went down -5.68%.

Which hedge fund is a major shareholder of Medicus Pharma Ltd?

Currently, no hedge funds are holding shares in MDCX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Medicus Pharma Ltd

Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutic assets, with an emphasis on non-invasive treatments for skin cancer.

Medicus Pharma Ltd (MDCX) Earnings & Revenues

Historic Earnings Reports

MDCX Stock 12 Month Forecast

Average Price Target

$6.00

▲(310.96% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","3":"$3","5":"$5","7":"$7","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$6.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1,3,5,7],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.42,0.8492307692307692,1.2784615384615385,1.7076923076923076,2.136923076923077,2.566153846153846,2.9953846153846153,3.4246153846153846,3.853846153846154,4.283076923076924,4.712307692307692,5.141538461538461,5.570769230769231,{"y":6,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.42,0.8492307692307692,1.2784615384615385,1.7076923076923076,2.136923076923077,2.566153846153846,2.9953846153846153,3.4246153846153846,3.853846153846154,4.283076923076924,4.712307692307692,5.141538461538461,5.570769230769231,{"y":6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.42,0.8492307692307692,1.2784615384615385,1.7076923076923076,2.136923076923077,2.566153846153846,2.9953846153846153,3.4246153846153846,3.853846153846154,4.283076923076924,4.712307692307692,5.141538461538461,5.570769230769231,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.46,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.6,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.99,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.96,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.32,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.95,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.08,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.24,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.44,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.98,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.53,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.5,"date":1772323200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.42,"date":1775001600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 18</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >